Identification of novel targets in the treatment of lung cancer

2016 Fiscal Year Final Research Report

• Project/Area Number: 26293318
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Respiratory surgery
• Research Institution: Okayama University
• Principal Investigator: Miyoshi Shinichiro 岡山大学, 医歯(薬)学総合研究科, 教授 (00190827)
• Co-Investigator(Kenkyū-buntansha): 豊岡 伸一 岡山大学, 医歯(薬)学総合研究科, 教授 (30397880) ; 宗 淳一 岡山大学, 大学病院, 講師 (90559890) ; 山本 寛斉 岡山大学, 大学病院, 助教 (40467733) ; 佃 和憲 岡山大学, 大学病院, 講師 (20346430) ; 阪口 政清 岡山大学, 医歯(薬)学総合研究科, 准教授 (70379840) ; 片山 博志 岡山大学, 医歯(薬)学総合研究科, 准教授 (90713975)
• Research Collaborator: SHIEN Kazuhiko ; SUZAWA Ken ; OHTSUKA Tomoaki
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 肺癌 / HER2 / 遺伝子変異 / チロシンキナーゼ阻害剤

Outline of Final Research Achievements

Recent developments in the genomic characterization of tumors have contributed to novel therapeutic approaches, and some molecular-targeted therapies based on the genetic profiles of tumors have improved patient survival. Human epidermal growth factor 2 (HER2) is a member of the HER family containing four receptor tyrosine kinases. Recently, we have identified novel mutations in the transmembrane domain of HER2 in lung adenocarcinomas. In this study, we clarified that these mutations could be oncogenic alterations of lung cancer. We also investigated the efficacy of afatinib as a HER2-targeted therapy in these HER2 altered lung cancer cells. In addition, we clarified a novel HER2 binding protein cytokeratin 19 (KRT19), and investigated the impact of KRT19 and HER2 interactions in signal transduction pathways to decode their possible roles in oncogenesis.

Free Research Field

胸部悪性腫瘍（肺癌・悪性胸膜中皮腫）おける治療感受性・抵抗性に関する研究、肺癌の外科治療